News
GlobalData on MSN21h
FDA grants breakthrough status to uniQure’s Huntington’s disease therapyThe US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...
Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback